reports
Soleno Therapeutics Announces Pricing of Approximately $138 Million Pu...
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the pricing of the underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $46.00 per share. The gross proceeds of the public offering are expected to be approximately $138.0 million, before deducting ...
Dorchester Minerals, L.P. Announces First Quarter Results
Dorchester Minerals, L.P. Announces First Quarter Results DALLAS, May 02, 2024 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP) announced today the Partnership’s net income for the quarter ended March 31, 2024 of $18,167,000, or $0.44 per common unit. A comparison of the Partnership’s consolidated results for the quarter ended March 31, 2024 and 2023 are set forth below: Three Months Ended March 31, 2024 2023Operating Revenues $30,979,000 $40,167,000Net Income $18,167,000 $28,070,000Net Income Per Common Unit $0.44 $0.71 The Partnership previously ...
Soleno Therapeutics Announces Proposed Public Offering of Common Stock
Soleno Therapeutics Announces Proposed Public Offering of Common Stock REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), ("Soleno" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Soleno intends to grant the underwriters a 30-day option to purchase an additional number of shares of common stock equal to 15% of the aggregate number of shares o...
Reed’s Schedules First Quarter 2024 Conference Call for May 14 at 5:00...
Reed’s Schedules First Quarter 2024 Conference Call for May 14 at 5:00 p.m. ET NORWALK, Conn., April 30, 2024 (GLOBE NEWSWIRE) -- Reed’s, Inc. (OTCQX: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, will host a conference call on Tuesday, May 14, 2024 at 5:00 p.m. Eastern time to discuss its financial results for the three months ended March 31, 2024. The Company’s results will be reported in a press release prior to the call. Reed’s management will host the conference call, followed by a question-and-answer period. Da...
Soleno Therapeutics Announces Peer-Reviewed Publication of Data Compar...
Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome Statistically Significant Improvements with DCCR Compared to Natural History of PWS from the PATH for PWS Study in Hyperphagia and PWS-related Behaviors REDWOOD CITY, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the publication of the comparison of results from the Company’s Phase ...
Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S...
Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS) First Ever Breakthrough Designation for a Drug Being Developed for PWS Designation is Based on Data from the Phase 3 Program for DCCR Planned Submission of a New Drug Application (NDA) for DCCR Remains on Track for Mid-2024 REDWOOD CITY, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing R...
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to six new employees. The independent members of the Board of Directors of Soleno approved the grant of non-qualified stock options to purchase 96,500 shares of common stock to six employees as an ind...
Dorchester Minerals, L.P. Announces Its First Quarter Distribution
Dorchester Minerals, L.P. Announces Its First Quarter Distribution DALLAS, April 18, 2024 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (NASDAQ:DMLP) announced today the Partnership’s first quarter 2024 cash distribution. The distribution of $0.781837 per common unit represents activity for the three-month period ended March 31, 2024 and is payable on May 9, 2024 to common unitholders of record as of April 29, 2024. Cash receipts attributable to the Partnership’s Royalty Properties during the first quarter totaled approximately $24.5 million. Approximately 71% of these receipts reflect o...
Reed’s Reports Fourth Quarter and Full Year 2023 Results and Issues 20...
Reed’s Reports Fourth Quarter and Full Year 2023 Results and Issues 2024 Financial Outlook Sixth Consecutive Quarter of YoY Operating Expense and Profitability Improvements Execution of Optimization Initiatives Leads to Material Improvement in FY 2023 Operating Loss and Modified EBITDA NORWALK, Conn., March 28, 2024 (GLOBE NEWSWIRE) -- Reed’s, Inc. (OTCQX: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, is reporting financial results for the three and twelve months ended December 31, 2023. Q4 2023 Financial Highlight...
Dorchester Minerals, L.P. Announces Acquisition of Mineral Interests
Dorchester Minerals, L.P. Announces Acquisition of Mineral Interests DALLAS, March 28, 2024 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP) announced today it completed an acquisition of mineral interests totaling approximately 1,485 net royalty acres located in two counties in Colorado. The transaction was structured as a non-taxable contribution and exchange. The contributing entities conveyed their interests to the Partnership in exchange for 505,369 common units representing limited partnership interests in Dorchester Minerals, L.P. Dorchester Mineral...
Assured Guaranty Ltd: 1 director
A director at Assured Guaranty Ltd sold 55,000 shares at 92.435USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Reed’s Schedules Fourth Quarter and Full Year 2023 Conference Call for...
Reed’s Schedules Fourth Quarter and Full Year 2023 Conference Call for March 28 at 5:00 p.m. ET NORWALK, Conn., March 19, 2024 (GLOBE NEWSWIRE) -- Reed’s, Inc. (OTCQX: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, will host a conference call on Thursday, March 28, 2024 at 5:00 p.m. Eastern time to discuss its financial results for the three and twelve months ended December 31, 2023. The Company’s results will be reported in a press release prior to the call. Reed’s management will host the conference call, followed by...
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing R...
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to five new employees. The independent members of the Board of Directors of Soleno approved the grant of non-qualified stock options to purchase 144,300 shares of common stock to five employees as an ...
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quart...
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results REDWOOD CITY, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the fourth quarter and full-year ended December 31, 2023. Full Year 2023 and Recent Corporate Highlights Announced positive statistically significant top-line data from the randomized withdrawal ...
Dorchester Minerals, L.P. Announces 2023 Results
Dorchester Minerals, L.P. Announces 2023 Results DALLAS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP) announced today the Partnership’s net income for the year ended December 31, 2023 of $114,117,000 or $2.85 per common unit. A comparison of the Partnership’s consolidated results for the twelve month periods ended December 31, 2023 and 2022 are set forth below: Twelve Months Ended December 31, 2023 2022 Operating Revenues$163,799,000 $170,800,000 Net Income$114,117,000 $130,607,000 Net Income Per Common Unit$2.85 $3.35 ...
Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care...
Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference REDWOOD CITY, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at the TD Cowen 44th Annual Healthcare Conference on Monday, March 4, 2024, at 1:30 PM Eastern Time. A live audio webcast and replay of the presentation will be available in the Investors section on the Company’s...
Reed’s Announces Limited Waiver and Amendment with its Secured Note Ho...
Reed’s Announces Limited Waiver and Amendment with its Secured Note Holder, Closing of a $3.8 Million SAFE and Planned Rights Offering to Stockholders Strengthening Capital Structure and Balance Sheet, Bringing Up to $6 Million of New Equity Capital Following Strong Close to 2023 NORWALK, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Reed’s, Inc. (OTCQX: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, today announced it has entered into a Limited Waiver, Deferral and Amendment and Restatement Agreement (the “Amendment”) wit...
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
TCBI TEXAS CAPITAL BANCSHARES INC.
PBF PBF ENERGY INC. CLASS A
NYCB NEW YORK COMMUNITY BANCORP INC.
NBTB NBT BANCORP INC.
MKL MARKEL CORPORATION
CVBF CVB FINANCIAL CORP.
CRMT AMERICA'S CAR-MART INC.
CPRX CATALYST PHARMACEUTICALS
CODI COMPASS DIVERSIFIED HOLDINGS
BERY BERRY GLOBAL GROUP INC
ADVM ADVERUM BIOTECHNOLOGIES
UPS UNITED PARCEL SERVICE INC. CLASS B
VIRT VIRTU FINANCIAL INC. CLASS A
RLMD RELMADA THERAPEUTICS
THR THERMON GROUP HOLDINGS
OVLY OAK VALLEY BANCORP
CIZN CITIZENS HOLDING CO.
CLSD CLEARSIDE BIOMEDICAL INC
RMCF ROCKY MOUNTAIN CHOCOLATE FACTORY INC.
KREF KKR REAL ESTATE FINANCE TRUST
DMLP DORCHESTER MINERALS L.P.
NEE NEXTERA ENERGY
MAV INC.
CLF PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
QNBC CLIFFS NATURAL RESOURCES INC.
RCUS QNB CORP.
AKTS ARCUS BIOSCIENCES
SKYE AKOUSTIS TECHNOLOGIES INC
HROW NEMUS BIOSCIENCE INC
PAYS HARROW HEALTH INC.
ACET PAYSIGN INC
ATXS ADICET BIO INC
TBBK ASTRIA THERAPEUTICS INC
COLB THE BANCORP
BPRN INC.
CRBP COLUMBIA BANKING SYSTEM
PCSA INC.
BANK OF PRINCETON
CORBUS PHARMACEUTICALS HOLDINGS INC.
PROCESSA PHARMACEUTICALS INC
- Jonathan Moreland
UPS UNITED PARCEL SERVICE INC. CLASS B
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
DMLP DORCHESTER MINERALS L.P.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
ATXS ASTRIA THERAPEUTICS INC
TBBK THE BANCORP
VPV INC.
BPRN INVESCO PA VALUE MUNI INC TST
BANK OF PRINCETON
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
TLYS TILLYS
TCBI TEXAS CAPITAL BANCSHARES INC.
STAA STAAR SURGICAL CO.
PBF PBF ENERGY INC. CLASS A
OPK OPKO HEALTH INC.
LPSN LIVEPERSON INC.
CODI COMPASS DIVERSIFIED HOLDINGS
PESI PERMA-FIX ENVIRONMENTAL SERVICES INC.
RLMD RELMADA THERAPEUTICS
ADC AGREE REALTY CORPORATION
FBK FB FINANCIAL CORPORATION
RMCF ROCKY MOUNTAIN CHOCOLATE FACTORY INC.
DMLP DORCHESTER MINERALS L.P.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
CLF CLIFFS NATURAL RESOURCES INC.
JGH NUVEEN GLB HG
CMXC CELL MEDX
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
QNBC QNB CORP.
RCUS ARCUS BIOSCIENCES
AKTS AKOUSTIS TECHNOLOGIES INC
TLRY TILRAY
PAYS PAYSIGN INC
FBIO FABIEN CORP
ACET ADICET BIO INC
GRPN GROUPON INC.
VRDN VIRIDIAN THERAPEUTICS INC
AGL AGILON HEALTH
TBBK INC.
MPA THE BANCORP
SLDB INC.
COLB BLACKROCK MUNIYIELD PENNSYLVANIA FD
CRBP SOLID BIOSCIENCES INC
LSXMK COLUMBIA BANKING SYSTEM
INC.
CORBUS PHARMACEUTICALS HOLDINGS INC.
LIBERTY SIRIUSXM GROUP
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.